Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

• Status: NOT_YET_RECRUITING
• Trial end date: 2028-09-15

Summary

This is a multi-center, phase II, prospective study. The main purpose of study is to evaluate the efficacy and safety of Glofitamab plus Polatuzumab vedotin and Zuberitamab in patients with newly diagnosed diffuse large B-cell lymphoma.

• Phase: PHASE2

Details

• Lead Sponsor: Li Zhiming
• Treatments: Cyclophosphamide; Doxorubicin; glofitamab; polatuzumab vedotin; Prednisone